vasotop p 1,25mg δισκίο
intervet international bv - ramipril 1,25 mg/tab - tablets - ace inhibitor - dogs
vasotop p 2,5 mg δισκίο
intervet international bv - ramipril 2,5 mg/tab - tablets - ace inhibitor - dogs
vasotop p 5 mg δισκίο
intervet international bv - ramipril 1,25 mg/tab - tablets - ace inhibitor - dogs
difene dual release 100mg modified-release capsule, hard
medilink pharmaceuticals ltd (0000003162) 30 armenias, strovolos, 1640, 26576 - diclofenac sodium - modified-release capsule, hard - 100mg - diclofenac sodium (0015307796) 100mg - diclofenac
difene dual release 75mg capsule,hard
medilink pharmaceuticals ltd (0000003162) 30 armenias, strovolos, 1640, 26576 - diclofenac sodium - capsule,hard - 75mg - diclofenac sodium (0015307796) 75mg - diclofenac
evorel 50mcg/24h transdermal patch
janssen-cilag international nv (0000003494) turnhoutseweg, 30, beerse, b-2340 - estradiol - transdermal patch - 50mcg/24h - estradiol (0000050282) 3.2mg - estradiol
carvilia 25mg/tab δισκιο
leovan Μ.ΛΕΩΝ & ΣΙΑ ΕΕ (0000003924) Μαινάνδρου 54,, 104 32, Αθήνα, 104 32 - carvedilol - ΔΙΣΚΙΟ - 25mg/tab - 0072956093 carvedilol 25.000000 mg - carvedilol
carvilia 6.25mg/tab δισκιο
leovan Μ.ΛΕΩΝ & ΣΙΑ ΕΕ (0000003924) Μαινάνδρου 54,, 104 32, Αθήνα, 104 32 - carvedilol - ΔΙΣΚΙΟ - 6.25mg/tab - 0072956093 carvedilol 6.250000 mg - carvedilol
carvilia 12.5mg/tab δισκιο
leovan Μ.ΛΕΩΝ & ΣΙΑ ΕΕ (0000003924) Μαινάνδρου 54,, 104 32, Αθήνα, 104 32 - carvedilol - ΔΙΣΚΙΟ - 12.5mg/tab - 0072956093 carvedilol 12.500000 mg - carvedilol
mekinist
novartis europharm limited - trametinib - Μελανώμα - Αντινεοπλασματικοί παράγοντες - melanomatrametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 και 5. trametinib monotherapy has not demonstrated clinical activity in patients who have progressed on a prior braf inhibitor therapy (see section 5. adjuvant treatment of melanomatrametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with stage iii melanoma with a braf v600 mutation, following complete resection. Μη-μικροκυτταρικό καρκίνο του πνεύμονα (nsclc)trametinib σε συνδυασμό με dabrafenib ενδείκνυται για τη θεραπεία ενήλικων ασθενών με προχωρημένο μη-μικροκυτταρικό καρκίνο του πνεύμονα με ένα braf v600 mutation.